Literature DB >> 10810411

Serrated adenoma: a clinicopathological, DNA ploidy, and immunohistochemical study.

M Iwabuchi1, H Sasano, N Hiwatashi, T Masuda, T Shimosegawa, T Toyota, H Nagura.   

Abstract

AIMS: Serrated adenoma (SA) is a relatively newly defined entity of colorectal neoplasm. In this study, we examined the cell proliferation, DNA ploidy, and clinicopathological features of SA in order to investigate its biological features. METHODS AND
RESULTS: We reviewed 10,532 polypectomy specimens of the colorectum obtained from Japanese cases between 1974 and 1998 at Tohoku University Hospital. In total, 193 cases of SA were detected. We first examined clinical features of these cases by reviewing the charts, and then studied cell proliferation using immunohistochemistry of Ki-67 and topoisomeraseIIa, p53 immunoreactivity and DNA ploidy. Results were subsequently compared with those of tubular adenoma (TA) and hyperplastic polyp (HP). Mean size of SA (8.6 +/- 4.6 mm) was significantly larger than those of TA (7.3 +/- 4.6 mm) and HP (5.6 +/- 3.0 mm). More than 80% of SA were protuberant in macroscopic appearance. SA was located predominantly in the sigmoid colon and rectum. Incidences of concomitant carcinoma in HP, SA and TA were 0.4% (1 out of 263), 4.1% (8 out of 193) and 10.3% (809 out of 7838), respectively. Labeling indices for Ki-67 and topoisomeraseIIa in HP, SA and TA were as follows: Ki-67--24.2%, 30.8%, 39.5% and topoisomeraseIIa--15.3%, 16.1%, 23.9%, respectively. In SA, p53 immunoreactivity was detected in the intramucosal carcinoma co-existing with the serrated component. Two out of the ten SA cases examined demonstrated non-diploid patterns of DNA ploidy.
CONCLUSION: SA is a distinct colorectal neoplastic lesion with the potential of malignant transformation similar to that of tubular adenoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810411

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Serrated adenoma in familial adenomatous polyposis: relation to germline APC gene mutation.

Authors:  T Matsumoto; M Iida; Y Kobori; M Mizuno; S Nakamura; K Hizawa; T Yao
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 3.  Significance of serrated polyps of the colon.

Authors:  Rachel J Groff; Russell Nash; Dennis J Ahnen
Journal:  Curr Gastroenterol Rep       Date:  2008-10

4.  Molecular characteristics of serrated adenomas of the colorectum.

Authors:  E J Sawyer; A Cerar; A M Hanby; P Gorman; M Arends; I C Talbot; I P M Tomlinson
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

5.  Serrated adenoma is a risk factor for subsequent adenomatous polyps.

Authors:  Emily Glazer; Vidushi Golla; Robin Forman; Hongfa Zhu; Gabriel Levi; Henry C Bodenheimer
Journal:  Dig Dis Sci       Date:  2008-03-05       Impact factor: 3.199

6.  Three-dimensional reconstruction and fractal geometric analysis of serrated adenoma.

Authors:  Masahiro Iwabuchi; Mareyuki Endoh; Nobuo Hiwatashi; Yoshitaka Kinouchi; Tooru Shimosegawa; Takayuki Masuda; Takuya Moriya; Hironobu Sasano
Journal:  Jpn J Cancer Res       Date:  2002-03

7.  Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions.

Authors:  Jane C Figueiredo; Michael N Passarelli; Wei Wei; Dennis J Ahnen; Jeffrey S Morris; Lynda Corley; Trupti Mehta; Angela N Bartley; Gail McKeown-Eyssen; Robert S Bresalier; Elizabeth L Barry; Ajay Goel; Goretti Hernandez Mesa; Stanley R Hamilton; John A Baron
Journal:  PLoS One       Date:  2021-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.